ABUS vs PNC · P/E 5.4, rev $6.2M vs P/E 14, rev $23.10B
Arbutus Biopharma Corp (ABUS) versus PNC Financial Services Group Inc (PNC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
PNC Financial Services Group Inc (PNC) is a banks - regional company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported PNC revenue for 2025-12-31 was $23.10B. Net income was $7.00B. Revenue was up 7.2% from 2024-12-31 to 2025-12-31. PNC currently screens at market cap $77.76B and trailing P/E 13.9.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. PNC currently screens at market cap $77.76B and trailing P/E 13.9.
Not investment advice. Open the ABUS and PNC stock pages for the full models.
Not investment advice.